Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies

NCT02862275 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT02862275
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02862275 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Pilot Study of Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 1
Overall status
Active, not recruiting
Start date
May 24, 2017
Completion date
November 21, 2026
Enrollment
40 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

hematopoietic and lymphoid cell neoplasm, metastatic malignant solid neoplasm, unresectable malignant solid neoplasm